EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 3 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab MOST POPULAR Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... April 19, 2023 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 What can elephants teach us about cancer? August 12, 2023 Cancer Research UK announces appointment of new Chair March 28, 2023 Load more HOT NEWS Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer The Gift of Time Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal...
